brexpiprazole
Antipsychotic • Brands: REXULTI
Last reviewed: 2025-09-23
General information
- Class: Antipsychotic
- Common US brands: REXULTI
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-09-23
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
D2/D3 partial agonist; 5‑HT1A partial agonist; 5‑HT2A antagonist.
Metabolism & Half‑life
- Metabolism: CYP3A4, CYP2D6
- Half‑life: Steady-state mean 91 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- REXULTI label — DailyMed
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
- AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology — Pharmacopsychiatry (2018)
- Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a randomized, double-blind, placebo-controlled trial — Schizophrenia Research (2015)
- Adjunctive brexpiprazole 1 and 3 mg/d for patients with major depressive disorder: a randomized, double-blind, placebo-controlled study — The Journal of Clinical Psychiatry (2015)